Premium
Dose‐response studies of quazepam
Author(s) -
Kales Anthony,
Scharf Martin B,
Bixler Edward O,
Schweitzer Paula K,
Jacoby Judith A,
Soldates Constantin R
Publication year - 1981
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1981.148
Subject(s) - benzodiazepine , insomnia , clinical pharmacology , drug , pharmacology , medicine , drug administration , anesthesia , hypnotic , receptor
Quazepam, an investigational benzodiazepine, was evaluated in doses of 7.5, 15, and 30 mg in a 12‐night protocol including four nights of drug trial. All three doses were effective in inducing and maintaining sleep, with the highest degree of effectiveness after the first drug night. Carry‐over effectiveness, which was seen after withdrawal of all three doses, persisted throughout the withdrawal period after the 30‐mg dose. Quazepam's effects during both drug use and withdrawal appeared to be dose related; 15 mg induced a greater reduction in wake time after sleep onset than the 7.5‐mg dose, and 30 mg induced even greater differences in both wake time after sleep onset and total wake time. Subjective reports of improved sleep were in general agreement with the objective data at each dose level. Side effects appeared to be dose related in terms of severity. The efficacy and comparatively less severe side effects of the 7.5‐and 15‐mg doses of quazepam suggest that these doses may be optimal when the drug is considered for the adjunctive treatment of insomnia. Clinical Pharmacology and Therapeutics (1981) 30, 194–200; doi: 10.1038/clpt.1981.148